An observational study in HIV Infections, sponsored by Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida. Recruiting at 1 site in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-10.
Sponsored by Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 278 studies in HIV Infections with a site in France — 19 open to participants now, 27 under way, 5 of them phase 3. HIV Infections · France.
Among the 278 studies in HIV Infections with a site in France, this one is the 38th largest by planned enrollment of the 59 observational ones that give a count, is one of 9 that started in 2024, is one of 59 observational ones, reaches primary completion later than 5 of the 26 other live ones, and was the 262nd registered.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →19 of the 278 studies in HIV Infections with a site in France are open now. Recruiting first, the newest first:
Nantes University Hospital · Sites in France
Ages 18+
ViiV Healthcare · Sites in France, United States, Argentina and 11 more countries
Ages 18+
Casper Rokx · Sites in France, Belgium, Germany and 7 more countries
Ages 18+ · Healthy volunteers
University Hospital, Strasbourg, France · Sites in France
Ages 18+
University Hospital, Montpellier · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
278 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 72 · Phase 3 94 · Phase 4 18
First in 1999; this study’s year is marked. 9 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is below the median of 200 across 781 observational studies indexed under HIV Infections.
Median enrollment 186 across the 213 interventional studies, 200 across the 59 observational. Of the 232 that completed or were terminated, 70 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
111 of 278 have an industry lead sponsor. The 10 most frequent:
Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida is the lead sponsor of 20 studies on the registry; 6 are open to participants now.
Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida has 8 studies filed under HIV Infections — fewer than ten, so there is no comparison to draw.
4 of the studies in HIV Infections with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03296202University Hospital, BordeauxRisk of Morbidity, Mortality and Long-term Monitoring of Antiretroviral Treatment in People Living With HIV | 2026-12 |
| NCT06441123University Hospital, MontpellierDevelopment of a New Family of HIV Latency Regulators (LRAs) Targeting the Tat Viral Protein | 2027-02-10 |
| NCT07552038Nantes University HospitalDental Management of Patients With HIV in Pays de la Loire | 2027-05-30 |
| NCT07202546ViiV HealthcareA Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study) | 2027-10-28 |
Add all 4 to your calendar (.ics) → With an account.
Among the 278 studies in HIV Infections with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Main objective is:
The alterations that affect the innate and adaptive immune cell compartments in HIV-infected patients are reminiscent of the process of immune aging, characteristic of old age. These alterations, the presumed cause of which is the chronic systemic immune activation established in patients, contribute to the depletion of lymphoid resources which probably leads to the decline of immune competence with the progression of HIV disease.
The comparison between HIV-1-infected patients and uninfected older adults goes beyond the mere appearance of immunosenescence and extends to the deterioration of a number of physiological functions linked to inflammation and to systemic aging.
By inducing persistent and lasting immune activation, HIV-1 infection is now considered a model of accelerated immunosenescence and systemic aging. During this process, the immune system quickly becomes exhausted, because the source of its exhaustion (i.e. HIV) cannot be eliminated.
To determine which factors may contribute to immunosenescence in HIV-1 infection, we propose an extensive immune and virological evaluation in patients who participated in a cross-sectional assessment of immune functions and TEMPO-1 viral reservoirs after 15 years of evolution in order to determine their immune and viral trajectories, to compare these trajectories with the major clinical events and the comorbidities occurring in them.
Growing old with HIV has become a reality thanks to major advances in antiretroviral therapy. Nearly 40 years after the discovery of the AIDS virus, there are more and more seniors living with HIV. Currently, the median age of HIV-positive people in France is 49 years old. 50% of HIV-positive people are over 50 years old (compared to 8.5% in 1993, 28% in 2010) and 16% over 60 years old. As for discoveries of seropositivity, 20% are in people over 50 years old. According to data from the Dutch ATHENA cohort, the proportion of HIV-infected people aged 50 and over is expected to increase to 73% in 2030.
Thus, if HIV infection has become a chronic disease, with lower mortality Investigator observe a consequent increase in age-related non-infectious comorbidities. Total healthy life expectancy remains reduced among PLHIV compared to uninfected people of the same age, and more than 50% of deaths are due to non-AIDS comorbidities. This polypathology occurs more frequently and at a younger age than in the general population, and notably combines cancers, risk factors and cardiovascular diseases, neurocognitive, bone diseases and chronic renal insufficiency. In 2030, it is estimated that 84% of PLHIV will have at least one of these comorbidities (vs. 29% in 2010), and that 28% will have at least 3, mainly cardiovascular. Some of these comorbidities are linked to the long-term use of ARVs (reverse transcriptase inhibitors, protease inhibitors, integrase inhibitors) leading in particular to metabolic toxicities (dyslipidemia, insulin resistance), renal, bone, endothelial and mitochondrial. However, these toxicities have decreased over time and with pharmacological progress.
n addition to individual or environmental factors such as smoking, a sedentary lifestyle, and classic cardiovascular risk factors, HIV seems to contribute to an acceleration of aging.
The finding of an increased prevalence of non-HIV-related comorbidities such as cardiovascular disease, cancer, renal failure, liver disease, osteopenia and osteoporosis, as well as neurocognitive impairments is reminiscent of classic complications among elderly people with a biological profile marked by inflammation.
Another point in common between PLHIV and the elderly is their prolonged exposure to medications, often constituting polypharmacy.
Thus, antiretroviral molecules, taken by patients for decades for the majority of them, have unfortunately been responsible for various toxicities. First generation ARVs caused cellular disorders with mitochondrial damage for NRTIs such as zidovudine, didanosine or stavudine, metabolic disorders with protease inhibitors. However, the most recent class of molecules, INIs, is not free from toxicities. Indeed, several studies have shown abnormal weight gain with a risk of diabetes and more recently hypertension.
The biological hallmarks of aging are now better understood and include stem cell exhaustion, genomic instability, telomere attrition, impaired intercellular communication, epigenetic alterations, loss of proteostasis, mitochondrial dysfunction and cellular senescence.
Immunologically, aging is associated with a decline in the competence of the immune system called immunosenescence. It is characterized by several features that affect the adaptive and innate immune compartment, as well as the hematopoietic compartment. It is also associated with a high level of secretion of pro-inflammatory cytokines at baseline, called "inflammation", leading to a decreased ability to mount an effective immune response to antigens. Investigators classically describe:
These global immune changes observed with age contribute in particular to morbidity and mortality linked to infections (in particular via a reduction in the vaccine response) and cancers.
In 2007/2008, with the aim of describing and understanding the different viral and immune phenomena in treated or untreated PLHIV, we carried out a cross-sectional observational study on 240 patients carrying HIV-1.
The TEMPO study included a similar assessment of immune performance in an age- and sex-matched control population. This TEMPO study allowed us to establish the following conclusions:
Importantly, disease progression despite elite control of HIV replication or virologic success on antiretroviral therapy has been associated with persistent damage to the lymphopoietic system or exhaustion of lymphopoiesis.
These results highlight the importance of primary hematopoietic resources in HIV pathogenesis and response to antiretroviral therapy.
TEMPO-2 is a cross-sectional study of PLHIV which will evaluate in depth the immuno-virological status of 100 patients studied in the same way 15 years ago (TEMPO-1). The complete history of clinical and biological events will be analyzed over their 15 years of follow-up in the same hospital.
The study includes two groups: one comprising HIV-infected patients (100 PLHIV) and the second comprising subjects not infected with HIV. Both groups participated in the initial study (TEMPO-1) conducted 15 years ago, with an in-depth assessment of immune and virological status.
The immune aging index of this HIV population will be compared to that of a control population of non-HIV subjects who both participated in TEMPO-1 in 2007/2008.
Investigator will focus on the dynamics of immune resources, particularly on hematopoietic progenitors. This approach will allow us to follow the biological trajectory of relevant immune factors and assess how these variables evolve over time between the two time points.
HIV-infected individuals and non-HIV infected control group
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
measure of number of participants with the frequency of circulating leukocyte cells
Assessment of 32 biomarkers by Cytek Aurora cytometry to identify more than 15 populations of immune cells
Time frame: one year
measureof number of participants with the number of hematopoietic stem cells in peripheral blood and their ability to develop a myeloid or lymphoid lineage in culture
Assessment by culture
Time frame: one year
measure of number of participants with cytokines and chemokines, being associated with the appearance of comorbidities
Assessment by ultra-sensitive manner (Luminex and Quantérix technique)
Time frame: one year
Measure of number of participants with Microbial translocation markers
Assessment by Elisa technique
Time frame: one year
Measure of number of participants with the HIV viral reservoir (DNA)
Assessment by HIV DNA viral load (quantitative analysis) and by Sequencing of HIV in its DNA form (qualitative analysis: presence of resistance mutations, stop codons, insertions/deletions)
Time frame: one year
Ran from Apr 2024 to primary completion in Dec 2024, 7 months.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida